03 Oct 2026, 15:02 IST
Torrent Pharmaceuticals Limited
Motilal Oswal (MOFSL) · Neutral
The report notes Torrent's EBITDA growth of 47.1% YoY benefiting from JB Pharma consolidation, though PAT is expected to decline 9.3% YoY.
From HEALTHCARE MOFSL PR PG024, written by Motilal Oswal (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.